Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial
Primary result · MACEResult — go to the resultHazard ratio 1.60 95% CI 0.65–3.91- prematurely terminated
- Prematurely terminated due to halt of production of everolimus-eluting stents
Authors' conclusion
Due to its limited power, no definite conclusion can be drawn regarding complete revascularization strategy from the present study.
Study context
- Population
- Patients with STEMI and multivessel disease undergoing primary percutaneous coronary intervention (PCI)
- Participants
- 248 patients
- Comparison
- Immediate vs staged complete revascularization
- Primary endpoint
- MACE:
- Total death
- Recurrent MI
- Revascularization
- Follow-up
- 12 months
Methodological detailsmulticentre, prospective
- Multicentre
- Prospective
Primary result
MACE · 1 year
Hazard ratio
1.60
95% CI 0.65–3.91
Events by treatment group
Immediate vs Staged
HR 1.60 (95% CI 0.65–3.91)
As reported in the abstract
Further findings
| Outcome | Immediate | Staged | HR (95% CI) | |
|---|---|---|---|---|
| Total death | 9.7% | 2.8% | 3.53 (0.97–12.84) | |
| 0.050.21520Hazard ratio (log scale) |
Individual major adverse cardiovascular events (MACE) components, cardiac death, stroke
- No significant differences between the 2 groups
Safety
In-hospital complications (transfusion, bleeding, acute renal failure, acute HF)
- No significant differences between the 2 groups
Original publication
Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial. Am Heart J. Published 7 February 2023. doi:10.
Summarised from the published abstract; every number is checked against it